AbbVie lifts full-year outlook again, shares extend S&P 500 healthcare run

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 09:14.

AbbVie (US00287Y1091) tightened and lifted its full-year 2026 guidance after a strong first quarter, according to recent analyst summaries based on the company’s latest earnings release. A Bitget stock overview citing AbbVie’s Q1 2026 figures highlights the higher revenue and earnings targets for the year. The New York Stock Exchange-listed S&P 500 healthcare name has also seen a marked share-price move in June after a fresh analyst upgrade reported by MarketBeat.

What the updated guidance shows

Following a robust start to 2026, AbbVie increased its full-year revenue outlook to around 67.3 billion US dollars and raised its adjusted earnings-per-share target range to 14.08 to 14.28 dollars, according to the Bitget analysis based on the company’s guidance commentary. The Bitget overview summarizing AbbVie’s guidance changes describes these figures as an upgrade from previous expectations. Neuroscience revenue is now projected at roughly 12.6 billion dollars for 2026, implying growth of about 16 percent year on year under the company’s planning assumptions.

The same analysis notes that Wall Street’s average 12?month price target for AbbVie sits in the range of 215 to 225 dollars per share, with some more optimistic houses such as Bank of America cited with targets up to 245 dollars, reflecting ongoing confidence in margin expansion as Humira biosimilar pressure fades. The Bitget stock commentary consolidating analyst targets also points out that the investment narrative has shifted toward the newer immunology, neuroscience and aesthetics portfolio.

Analyst sentiment and recent share move

On the equity side, AbbVie shares on the NYSE closed at 243.50 US dollars on 25 June 2026, up about 3.7 percent on the day according to TradingKey data. TradingKey’s ABBV quote and performance data show a market capitalization around 430 billion dollars at that level. MarketBeat reports that this latest move followed an analyst upgrade, with the stock trading roughly 14 percent higher over the past 30 days as of late June. MarketBeat’s overview of AbbVie’s recent price action and analyst rating changes underscores that the sentiment shift is backed by both earnings momentum and improving growth visibility.

In addition, TrendSpider data point to a dividend yield of just over 3 percent at recent prices, which keeps AbbVie positioned as an income-oriented large-cap in the S&P 500 healthcare space while the share price has climbed more than 14 percent over the past month. TrendSpider’s technical and dividend snapshot for AbbVie also notes the next earnings date currently expected around 30 July 2026, which will offer the next check on whether the raised guidance remains intact.

The products behind AbbVie’s cash flows

AbbVie generates the bulk of its revenue from immunology, neuroscience, oncology and aesthetics therapies, with key brands including Skyrizi and Rinvoq in immunology, Vraylar in neuroscience, Imbruvica in oncology and Botox in aesthetics. Recent European Commission approvals extended Skyrizi to pediatric plaque psoriasis and broadened Maviret’s label to children from age three with hepatitis C, reinforcing the company’s foothold in immunology and virology. A Yahoo Finance article on AbbVie’s recent pediatric label expansions in Europe highlights how those moves open earlier treatment windows in high-need diseases.

Where the AbbVie stock trades today

The AbbVie shares (US00287Y1091) most recently closed on the NYSE at 243.50 US dollars on 2026-06-25, 16:00 Eastern Time, according to TradingKey, implying a market capitalization of around 430.5 billion US dollars at that price level. TradingKey’s latest AbbVie quote

This article provides factual information and context on the AbbVie shares and does not contain investment advice or a recommendation to buy or sell securities.